A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
Hayley Nehoff(University of Otago), Khaled Greish(Arabian Gulf University)
Cited by 32
Related Papers
Exploiting the enhanced permeability and retention effect for tumor targeting
|Drug Discovery Today|2006|1.8k
Macromolecular Therapeutics
|Clinical Pharmacokinetics|2003|279
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
|International Journal of Nanomedicine|2016|20
The Influence of Drug Loading on Caveolin-1 Mediated Intracellular Internalization of Doxorubicin Nanomicelles in vitro
|Journal of Nanomedicine & Nanotechnology|2014|14